drugset / Trial / NCT07168837
Letrozole and Cabergoline Versus Letrozole Alone in Ovulation Induction
RandomizedParallel-groupDouble-blindTreatment
Summary
Polycystic Ovarian Syndrome (PCOS) is the most common endocrine disorders in women of reproductive age. According to the World Health Organization (WHO) estimation revealed over 116 million women (3.4%) are affected by PCOS worldwide. Owing to the intricacy of this condition, various sets of diagnostic criteria have been initiated for the confirmation of PCOS which are: National Institute of Health, Rotterdam's Criteria, Androgen Excess and PCOS society. The prevalence of PCOS is estimated at about 4 to 21 % when it is diagnosed according to the Rotterdam criteria accounting for 75% of cases with anovulatory infertility.
Timeline
- Start
- 2023-01-10
- Primary completion
- 2024-05-01
- Completion
- 2024-05-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cabergoline | Small molecule | 0.5 mg | — |
| Comparator | Letrozole | Other / unclassified | 5 mg | Oral |